

Accepted Manuscript

Tumor Priming by Apo2L/TRAIL Reduces Interstitial Fluid Pressure and Enhances Efficacy of Liposomal Gemcitabine in a Patient Derived Xenograft Tumor Model

Bonnie L. Hylander, Arindam Sen, Sarah H. Beachy, Rose Pitoniak, Soumya Ullas, John F. Gibbs, Jingxin Qiu, Joshua D. Prey, Gerald J. Fetterly, Elizabeth A. Repasky

PII: S0168-3659(15)30090-0
DOI: doi: [10.1016/j.jconrel.2015.08.047](https://doi.org/10.1016/j.jconrel.2015.08.047)
Reference: COREL 7827

To appear in: *Journal of Controlled Release*

Received date: 28 April 2015
Revised date: 10 August 2015
Accepted date: 24 August 2015



Please cite this article as: Bonnie L. Hylander, Arindam Sen, Sarah H. Beachy, Rose Pitoniak, Soumya Ullas, John F. Gibbs, Jingxin Qiu, Joshua D. Prey, Gerald J. Fetterly, Elizabeth A. Repasky, Tumor Priming by Apo2L/TRAIL Reduces Interstitial Fluid Pressure and Enhances Efficacy of Liposomal Gemcitabine in a Patient Derived Xenograft Tumor Model, *Journal of Controlled Release* (2015), doi: [10.1016/j.jconrel.2015.08.047](https://doi.org/10.1016/j.jconrel.2015.08.047)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Tumor Priming by Apo2L/TRAIL Reduces Interstitial Fluid Pressure
and Enhances Efficacy of Liposomal Gemcitabine
in a Patient Derived Xenograft Tumor Model**

Bonnie L. Hylander^{1*}, Arindam Sen¹, Sarah H. Beachy², Rose Pitoniak¹, Soumya Ullas², John F. Gibbs³,
Jingxin Qiu⁴, Joshua D. Prey⁵, Gerald J. Fetterly⁵ and Elizabeth A. Repasky^{1*}

Depts. of ¹Immunology, ²Cell Stress, ³Surgical Oncology, ⁴Pathology and ⁵Medicine, Roswell Park Cancer
Institute, Buffalo NY

Note: BL Hylander and A Sen contributed equally to this work.

Corresponding Authors*:

Bonnie L. Hylander, PhD
Dept. of Immunology
MRC 208
Roswell Park Cancer Institute
Elm and Carlton
Buffalo, NY 14263

Telephone: 716-845-8612
Email: bonnie.hylander@roswellpark.org

Elizabeth A Repasky, PhD
Dept. of Immunology
CPG L5-321
Roswell Park Cancer Institute
Elm and Carlton
Buffalo, NY 14263

Telephone: 716-845-3133
Email: Elizabeth.repasky@roswellpark.org

Running title: Apo2L/TRAIL Reduces Interstitial Fluid Pressure

Keywords: Apo2L/TRAIL, patient tumor xenograft, interstitial fluid pressure, gemcitabine, liposomes, drug uptake

Download English Version:

<https://daneshyari.com/en/article/7862824>

Download Persian Version:

<https://daneshyari.com/article/7862824>

[Daneshyari.com](https://daneshyari.com)